Targeted immunotherapy for deadly prostate cancer shows promise in preclinical test

Scientists at Fred Hutch have identified a protein marker that may have potential as a way to guide targeted therapy to an aggressive subtype of prostate cancer. Tests in animal models showed promising results.

Read the full article here

Related Articles